LOS ANGELES--(BUSINESS WIRE)--
MedMen Enterprises Inc. (âMedMenâ or the âCompanyâ) (MMEN.CN) (MMNFF) today released its consolidated financial results for the third quarter of fiscal 2019. All financial information for the 13 week period ended March 30, 2019 is reported in U.S. dollars, unless otherwise indicated.
Management Commentary
âOver the past nine years, MedMen has built the most valuable retail brand in the cannabis industry by taking advantage of the land grab opportunity and scaling with speed to secure as many flagship assets as possible,â said Adam Bierman, MedMen co-founder and chief executive officer. âWe continue to march onward towards profitability. The biggest driver for this phase of the business remains revenue, which continues to increase significantly with new store openings and same store sales growth. Where we are impressively ahead of schedule is in leveraging our scale to create greater operational efficiencies across the organization. Execution keeps improving while corporate SG&A is decreasing.â
Since going public one year ago, MedMen has established a track record of success, including achieving a 7% market share in California (inclusive of revenue from pending and pre-closing revenue from recently closed acquisitions), an $11 billion cannabis market. The Company is slated to open 15 new locations across the U.S. during the remainder of calendar 2019. Of the planned locations, 12 will be in Florida, where MedMen is licensed for up to 35 locations.
Third Quarter 2019 Overview
Financial:
Retail Highlights:
Corporate Development:
Brand and Digital Strategy:
Capital Markets and Financing Activities:
Subsequent Events
Corporate Development:
Brand and Digital Strategy:
Corporate SG&A:
Capital Markets and Financing Activities:
Corporate Governance:
Third Quarter Fiscal Year 2019 Review
Consolidated:
For the third quarter of fiscal 2019, systemwide revenue was $36.6 million. This represents a 22% quarter-over-quarter increase over the fiscal 2019 second quarter ended December 30, 2018 and an 156% increase over the same quarter last year.
Gross profit for the third quarter of fiscal 2019, before biological asset adjustment, was $15.5 million, as compared to $13.3 million in the previous quarter. For the third quarter, gross profit margin after biological asset adjustment was 53.7%, compared to 53.2% in the previous quarter.
For the quarter, the Company reported an Adjusted EBITDA loss of $42.6 million, which decreased by 3% from the previous quarter. The Company reported a net loss attributable to the Company of $63.1 million, or loss of $0.20 per basic and diluted share attributable to MedMen Enterprises shareholders, for the third quarter of fiscal 2019, compared to a net loss of $64.6 million, or loss of $0.25 per share, for the second quarter of fiscal 2019.
Retail:
Systemwide retail revenue for the quarter increased by 16% to $34.6 million. This is based on 21 retail stores that were operational at the end of the quarter. The increase is primarily attributable to the Companyâs operations in Nevada and Arizona. Despite the typical slowdown in retail sales post-holiday season, the Company recorded positive same-store sales growth.
The Company recorded 53% retail gross margins for the quarter, which is in line with the last quarter. However, retail gross retail margins for California were up from 51% to 57%, reflecting increased purchasing power and supply chain optimization. Retail EBITDA margins decreased from 16.6% to 12.5% for the quarter, reflecting lower margins in medical markets such as Arizona and Illinois and increase in payroll costs. The Company expects margins to increase in the next quarter.
Cultivation and Manufacturing:
For the quarter, the Company reported $4.7 million adjusted EBITDA loss for cultivation and manufacturing, of which approximately $4.3 million was related to costs associated with the Companyâs Project Mustang facility in Nevada. These costs were expected during the ramp up period, and the Company expects to break-even by the end of the calendar year.
Corporate SG&A:
For the quarter, the Company recorded a 9% sequential reduction in corporate SG&A, contributing $37.5 million to adjusted EBITDA loss. The key drivers of the decrease were across marketing, legal and HR. The Company is targeting an overall 20% reduction in SG&A from the second quarter and expects the majority of cost savings to come from a decrease in corporate-level payroll.
Pre-Opening Expenses:
The Company incurred $4.6 million of pre-opening expenses in Q3, primarily driven by rent expenses of retail stores, cultivation/manufacturing sites and facilities that are not yet operational. This is up from $3.0 million in the previous quarter.
ADDITIONAL INFORMATION
Additional information relating to the Companyâs third quarter 2019 results is available on SEDAR at www.sedar.com in the Companyâs Interim Financial Statements and Management Discussion & Analysis (âMD&Aâ) for the quarter.
MedMen refers to certain non-IFRS financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), adjusted EBITDA (defined as earnings before interest, taxes, depreciation, amortization, less certain non-cash equity compensation expense, including one-time transaction fees and all other non-cash items) and four wall retail gross margins. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers.
Please see the âSupplemental Information (Unaudited) Regarding Non-IFRS Financial Measuresâ at the end of this press release and the MD&A for more detailed information regarding non-IFRS financial measures.
CONFERENCE CALL AND WEBCAST:
MedMen Enterprises will host a conference call and audio webcast with Chief Executive Officer and Co-Founder Adam Bierman and Chief Financial Officer Michael Kramer today at 5:00 pm Eastern to discuss the financial results in further detail.
Webcast Information:
A live audio webcast of the call will be available on the Events
and Presentations section of MedMenâs website at: https://investors.medmen.com/events-and-presentations/default.aspx.
Calling Information:
Toll Free Dial-In Number: (844) 559-7829
International Dial-In Number: (647) 689-5387
Conference ID: 1895524
ABOUT MEDMEN:
MedMen is a cannabis retailer with operations across the U.S. and flagship stores in Los Angeles, Las Vegas and New York. MedMenâs mission is to provide an unparalleled experience that invites the world to discover the remarkable benefits of cannabis because a world where cannabis is legal and regulated is a safer, healthier and happier world.
Learn more at www.medmen.com
Cautionary Note Regarding Forward-Looking Information and Statements
This press release contains certain âforward-looking informationâ within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute âforward-looking statementsâ within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMenâs beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMenâs control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as âplansâ, âexpectsâ or âdoes not expectâ, âis expectedâ, âbudgetâ, âscheduledâ, âestimatesâ, âforecastsâ, âintendsâ, âanticipatesâ or âdoes not anticipateâ, or âbelievesâ, or variations of such words and phrases or may contain statements that certain actions, events or results âmayâ, âcouldâ, âwouldâ, âmightâ or âwill be takenâ, âwill continueâ, âwill occurâ or âwill be achievedâ. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, information concerning proposed acquisitions, expectations regarding whether such proposed acquisitions will be consummated, including whether conditions to the consummation of the proposed acquisitions will be satisfied and whether the proposed acquisitions will be completed on the current terms, the timing for completing the proposed acquisitions, expectations for the effects of the proposed acquisitions (including on the Companyâs footprint, revenues and asset base) on the ability of the Company to successfully achieve business objectives, statements regarding annualized revenues, expectations for gross margins in the next quarter and expectations for the timing of cultivation and manufacturing operations to break even, and expectations for other economic, business, and/or competitive factors.